Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-384

Multidrug resistance (MDR) remains a critical bottleneck in successful treatment of osteosarcoma (OS). Luteolin is a flavonoid compound that has been verified to increase the sensitivity to antineoplastic drugs in many tumors. However, its roles in reversing MDR of OS and the potential underlying me...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Tao, Zhu, Wenjing, Kan, Xiaoli, Li, Ling, Wu, Dapeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048097/
https://www.ncbi.nlm.nih.gov/pubmed/35493691
http://dx.doi.org/10.1016/j.jbo.2022.100429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048097/
https://www.ncbi.nlm.nih.gov/pubmed/35493691
http://dx.doi.org/10.1016/j.jbo.2022.100429

Ejemplares similares